Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|---|
Income Statement | ||||||
Total Revenue | 372.80M | 263.40M | 78.50M | 131.40M | 53.60M | 25.90M |
Gross Profit | 371.40M | 263.40M | 78.50M | 131.40M | 53.60M | 21.80M |
EBITDA | -115.70M | -243.60M | -394.80M | -255.00M | -182.40M | -117.60M |
Net Income | -72.60M | -198.90M | -367.30M | -282.50M | -191.00M | -119.30M |
Balance Sheet | ||||||
Total Assets | 909.30M | 1.09B | 1.30B | 1.27B | 1.58B | 717.37M |
Cash, Cash Equivalents and Short-Term Investments | 861.20M | 1.04B | 1.26B | 1.21B | 1.50B | 688.53M |
Total Debt | 9.90M | 9.70M | 3.20M | 5.50M | 5.00M | 4.10M |
Total Liabilities | 300.00M | 529.70M | 644.60M | 703.90M | 799.90M | 75.11M |
Stockholders Equity | 609.30M | 561.70M | 660.00M | 564.90M | 781.70M | 642.26M |
Cash Flow | ||||||
Free Cash Flow | -399.00M | -261.10M | -350.70M | -280.30M | 554.70M | -96.20M |
Operating Cash Flow | -396.40M | -259.30M | -347.80M | -273.50M | 559.40M | -89.76M |
Investing Cash Flow | 347.70M | 34.70M | 203.50M | 242.80M | -1.31B | 164.25M |
Financing Cash Flow | 3.30M | 7.90M | 374.70M | 4.70M | 278.60M | 504.67M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
72 Outperform | 816.67M | 47.51 | 27.62% | ― | 35.89% | 0.00% | |
60 Neutral | 409.48M | 9.51 | 12.90% | ― | 1263.40% | 0.00% | |
49 Neutral | $552.83M | ― | -35.41% | ― | ― | ― | |
48 Neutral | 832.62M | -10.18 | -15.91% | ― | 83.36% | 22.27% | |
39 Underperform | 488.40M | -3.01 | 0.00% | ― | -80.09% | 60.14% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 8, 2025, Arvinas, in collaboration with Pfizer, announced that the FDA accepted their New Drug Application for vepdegestrant, a PROTAC ER degrader, for treating ER+/HER2- ESR1-mutated advanced or metastatic breast cancer. This acceptance, based on the Phase 3 VERITAC-2 trial, marks a significant step forward as vepdegestrant demonstrated improved progression-free survival compared to fulvestrant, potentially offering a new treatment option for patients with limited alternatives after first-line therapy.
The most recent analyst rating on (ARVN) stock is a Buy with a $18.00 price target. To see the full list of analyst forecasts on Arvinas Holding Company stock, see the ARVN Stock Forecast page.